Simultaneous Combined Intravenous Recombinant Tissue Plasminogen Activator and Endovascular Therapy for Hyperacute Middle Cerebral Artery M1 Occlusion

Abstract

We investigated the efficacy and safety of combined intravenous (IV) recombinant tissue plasminogen activator (rtPA) and simultaneous endovascular therapy (ET) for hyperacute middle cerebral artery (MCA) M1 occlusion.

Between October 2005 and April 2007, in the combined group, 22 patients eligible for IV rtPA, who were diagnosed as having MCA M1 occlusion, were treated with IV rtPA and simultaneous ET was initiated as soon as possible. The other patients were treated with IV rtPA alone (IV group A: n = 11). Between May 2007 and November 2008, all patients eligible for IV rtPA, who were diagnosed as having MCA M1 occlusion, underwent thrombolysis by IV rtPA alone (IV group B: n = 24).

The improvement of the National Institutes of Health Stroke Scale score at 24 hours was highest in the combined group (10 ± 4.1). In contrast, it was 5.1 ± 4.7 in the IV group A (P = 0.017) and 5.6 ± 5.6 in IV group B (P = 0.006). In the combined group, successful recanalization was observed in 18 of 22 patients with one symptomatic intracranial hemorrhage. The rate of mRS0–2 at three months was highest in the combined group, 36% in the IV group A and 33% in the IV group B (P = 0.008).

Simultaneous treatment with IV rtPA and ET improved the clinical outcome of MCA M1 occlusion without a significant increase of adverse effects in our study.

Keywords

thrombolysis acute stroke cerebral infarct endovascular treatment interventional neuroradiology

Get full access to this article

View all access options for this article.

References

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333: 1581–1587.

Neumann-Haefelin

du Mesnil de Rochemont

Fiebach

. Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle cerebral artery occlusion: A magnetic resonance imaging study. Stroke 2004; 35: 109–114.

Saqqur

Uchino

Demchuk

. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007; 38: 948–954.

Wolpert

Bruckmann

Greenlee

. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. Am J Neuroradiol 1993; 14: 3–13.

Furlan

Higashida

Wechsler

. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. J Am Med Asso. 1999; 282: 2003–2011.

Ogawa

Mori

Minematsu

. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. Stroke. 2007; 38: 2633–2639.

IMS II Trial Investigators. The Interventional Management of Stroke (IMS) II Study. Stroke. 2007; 38: 2127–2135.

IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke. 2004; 35: 904–911.

Shaltoni

Albright

Gonzales

. Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke? Stroke. 2007; 38: 80–84.

10.

Singer

Berkefeld

Lorenz

. Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. Cerebrovasc Dis. 2009; 27: 368–374.

11.

Smith

. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I. Am J Neuroradiol. 2006; 27: 1177–1182.

12.

Sugiura

Iwaisako

Toyota

Takimoto

. Simultaneous treatment with intravenous recombinant tissue plasminogen activator and endovascular therapy for acute ischemic stroke within 3 hours of onset. Am J Neuroradiol. 2008; 29: 1061–1066.

13.

Heiss

. Ischemic penumbra: Evidence from functional imaging in man. J Cereb Blood Flow Metab. 2000; 20: 1276–1293.

14.

Heiss

Kracht

Grond

. Early [(11)C] Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy. Stroke. 2000; 31: 366–369.

15.

Yamaguchi

Mori

Minematsu

. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006; 37: 1810–1815.

16.

Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003; 15: 222–229.

17.

TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985; 312: 932–936.

18.

Delgado-Mederos

Rovira

Alvarez-Sabin

. Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke. Stroke. 2007; 38: 955–960.

19.

Lewandowski

Frankel

Tomsick

. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke. 1999; 30: 2598–2605.

20.

Ernst

Pancioli

Tomsick

. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke. 2000; 31: 2552–2557.

21.

Hill

Barber

Demchuk

. Acute intravenous-intra-arterial revascularization therapy for severe ischemic stroke. Stroke. 2002; 33: 279–282.

22.

Lee

Kim

. Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke. Am J Neuroradiol. 2004; 25: 1470–1475.

23.

Rudolf

Grond

Stenzel

. Incidence of space-occupying brain edema following systemic thrombolysis of acute supratentorial ischemia. Cerebrovasc Dis. 1998; 8: 166–171.

24.

Montaner

Molina

Monasterio

. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003; 107: 598–603.